Management of Acute Myeloid Leukemia (AML) in Older Patients.
Curr Oncol Rep
; 22(10): 103, 2020 07 28.
Article
in En
| MEDLINE
| ID: mdl-32725515
ABSTRACT
PURPOSE OF REVIEW The acute myeloid leukemia (AML) treatment landscape has rapidly evolved over the past few years. These changes have several implications for the care of older adults (≥ 60 years), who have inferior clinical outcomes. We review decision-making in older adults, focusing on patient- and disease-related factors. We then summarize current treatment options, including multiple recently approved therapies, based on hypothetical clinical scenarios. RECENT FINDINGS:
In lieu of using chronological age to determine fitness, we highlight the importance of standardized fitness assessments using geriatric assessments. Next, we review intensive and lower-intensity treatment options in the upfront setting. We focus on multiple newly approved medications, including venetoclax, midostaurin, CPX-351, gemtuzumab, glasdegib, enasidenib, and ivosidenib, and their specific indications. Lastly, we briefly discuss supportive care of older adults with AML. Outcomes of older adults with AML remain poor; fortunately, there are many new promising treatment options. Personalized treatment plans based on patient- and disease-specific factors are essential to the care of older adults with AML.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Myeloid, Acute
/
Geriatric Assessment
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Aged
/
Humans
/
Middle aged
Language:
En
Journal:
Curr Oncol Rep
Journal subject:
NEOPLASIAS
Year:
2020
Document type:
Article
Affiliation country:
United States